Leukemia News

In this edition, outpatient HSCT feasible for older adults; ponatinib for newly diagnosed Ph+ALL; iomab-B may increase transplant access in relapsed/refractory AML and more.

Delaying antibiotic treatment beyond 1 hour from developing neutropenic fever did not affect OS among hospitalized patients with cancer, results from a retrospective study showed.

Time to engraftment after hematopoietic stem cell transplantation is an important outcome that institutions are legally required to report to the Center for International Blood and Marrow Transplant Research.

Survivors of blood or marrow transplants exhibited an increased risk for developing subsequent malignant neoplasms in the gastrointestinal tract, according to results of a cohort study published in JAMA Oncology.

Healio | HemOnc Today is excited to announce the nominees for its second annual Disruptive Innovators Awards in oncology and hematology.

Targeted conditioning with iodine (131I) apamistamab enabled older patients with relapsed or refractory acute myeloid leukemia to undergo allogeneic hematopoietic stem cell transplantation, according to results of the phase 3 SIERRA trial.

Children with acute lymphoblastic leukemia who resided along the U.S.-Mexico border appeared at higher risk for death than their counterparts in other areas of Texas, according to study results published in Cancer.

The economic cost of cancer worldwide from 2020 to 2050 will be $25.2 trillion in international dollars, according to results of a decision analytical modeling study published in JAMA Oncology.

Vedolizumab showed greater efficacy than placebo when added to standard prophylaxis for prevention of lower gastrointestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation, according to a study.

Only a decade ago, many in oncology considered chimeric antigen receptor T-cell therapy too fringe for real-world use.